A former pharmaceutical executive traded on nonpublic information about an antipsychotic drug’s development, avoiding $1.3 ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the following virtual investor conferences: ...

VP at Acadia Pharmaceuticals, pled guilty to insider trading, avoiding a $1.3M loss by illicitly selling shares ahead of a ...

Learn more about whether ACADIA Pharmaceuticals Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...

Acadia is seeing solid growth from its two products on the market. Check out the analysis of ACAD stock following Q4 numbers ...

Full Year 2024 Results Key Financial Results Revenue: US$957.8m (up 32% from ...

HC Wainwright reiterated their buy rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a report ...

ACADIA Pharmaceuticals has a one year low of $14.15 and a one year high of $24.27. Insiders Place Their Bets In related news, Director Elizabeth A. Garofalo sold 4,919 shares of the company’s ...

Acadia Pharmaceuticals (ACAD) and Saniona announced the completion of the two originally planned cohorts in their Phase 1 ...

Morgan Stanley assumed coverage of Acadia Pharmaceuticals (ACAD) with an Equal Weight rating and $20 price target The firm sees patent ...

Acadia (ACAD) delivered earnings and revenue surprises of -10.53% and 1.79%, respectively, for the quarter ended December ...